Fresenius stock holds steady as one-year performance turns negative
Published on 09/03/2026 at 09:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius stock (ISIN DE0005785604) last closed at 44.79 EUR on Xetra on September 1, 2026, leaving a one-year investment slightly in the red according to a performance review by finanzen.ch.
One-year return lags despite solid price level
Data compiled by finanzen.ch on September 2, 2026 shows that an investor who put 1,000 EUR into Fresenius stock one year earlier would see the position valued at 963.12 EUR at the Xetra closing price of 44.79 EUR on September 1, 2026.
This corresponds to a negative performance of 3.69 percent over twelve months, as the investment declined from 1,000 EUR to 963.12 EUR while the share price slipped from 46.50 EUR one year earlier to 44.79 EUR.
For investors, the picture is mixed: the share price remains close to the mid-40 EUR range, but the modest percentage loss underlines that Fresenius has not kept pace with stronger performers in the DAX segment over the same period.
Cross-venue quotes underline muted sentiment
The same finanzen.ch analysis notes that Fresenius stock was quoted at 41.61 Swiss francs in Swiss trading on September 2, 2026, representing a decline of 1.69 percent on that day.
This cross-venue weakness indicates that the cautious sentiment around Fresenius is visible not only on Xetra but also in Swiss trading, with investors across European markets pricing in similar expectations for the healthcare group.
Market observers point out that such small but persistent daily declines can weigh on short-term traders, even when the overall twelve-month move appears limited in percentage terms.
More background on Fresenius stock
Read further coverage, corporate disclosures and historical news flow on Fresenius to better understand the drivers behind the recent share performance.
Investor communication and recent presentation
Beyond the day-to-day trading data, Fresenius continues to address investors directly through presentations and events, including a presentation hosted by investor association SdK on September 2, 2026 in Munich, where the company outlined its current position and strategy.
According to the agenda published by SdK, Fresenius SE and Co. KGaA used the September 2, 2026 slot to provide an update for private investors and discuss its financial profile.
Such events play an important role for shareholders who want to evaluate whether the current mid-40 EUR price range and the twelve-month loss of 3.69 percent reflect an attractive entry point or simply a pause in a longer consolidation phase.
Fresenius Helios as a core healthcare brand
Within the group, a key operating pillar is Fresenius Helios, which runs a large network of hospitals and clinics and is a major contributor to the group healthcare services portfolio.
Helios facilities treat millions of patients per year and generate a substantial portion of Fresenius revenue, making operational efficiency and occupancy trends in this segment important for the overall earnings profile.
For many private investors, the visibility of Helios hospitals in the DACH region underscores Fresenius position as a core healthcare provider rather than a pure financial holding.
Fresenius stock stays anchored in the DAX environment
As of the Xetra close on September 1, 2026, Fresenius stock traded at 44.79 EUR with a one-year performance of minus 3.69 percent, placing it in the midfield of DAX healthcare names in terms of recent returns.
The stock remains a liquid DAX constituent on Xetra, which is relevant for index and ETF investors who require exposure to the German healthcare sector via blue-chip names like Fresenius.
Fresenius stock profile
- Company: Fresenius SE and Co. KGaA
- ISIN: DE0005785604
- Ticker: FRE
- Trading venue: Xetra
- Price (as of September 1, 2026): 44.79 EUR
- Sector / Industry: Health Care / Health Care Providers and Services
- Index membership: DAX 40
